GI
TGTX icon

Gradient Investments’s TG Therapeutics TGTX Stock Holding History

Gradient Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$34 – 1784
2023
Q4 		$34 Hold
2
– – ﹤0.01% 1780
2023
Q3 		$17 Sell
2
-310
-99% -$4.32K ﹤0.01% 1776
2023
Q2 		$7.75K Sell
312
-156
-33% -$4.03K ﹤0.01% 858
2023
Q1 		$7.04K Hold
468
– – ﹤0.01% 885
2022
Q4 		$5.54K Hold
468
– – ﹤0.01% 914
2022
Q3 		$3K Hold
468
– – ﹤0.01% 1092
2022
Q2 		$2K Buy
468
+158
+51% +$987 ﹤0.01% 1074
2022
Q1 		$3K Buy
310
+50
+19% +$579 ﹤0.01% 994
2021
Q4 		$5K Hold
260
– – ﹤0.01% 946
2021
Q3 		$9K Buy
+260
New +$8.04K ﹤0.01% 794

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gradient Investments's TGTX Position: Q1 2024 in Review

Gradient Investments sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 2 shares — an estimated $34 sold.

Gradient Investments first reported a position in TGTX in Q3 2021 and held it in 10 quarters. The position peaked at $9K in Q3 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Gradient Investments reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 2 TG Therapeutics shares in Q1 2024, an estimated $34.
  • Gradient Investments first reported a position in TG Therapeutics in Q3 2021 and held it in 10 quarters.
  • Gradient Investments's TG Therapeutics position peaked at $9K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.